Last updated: January 2024
GLP1 Receptor Agonist drugs (Semaglutide, Ozempic, Mounjaro, Wegovy, etc) have seen extensive testing and research in the past, due to their usage by people with type 2 Diabetes.
Finding all this research is hard, so here at glp1.guide we're trying to put together a list. Here's what we've found – most recent research first.
Observational Studies
Real‐world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study
Effects
Effect of tirzepatide on blood pressure levels in overweight/obese individuals without diabetes
GLP1-Agonists: effect in management of diabetes and weight loss in older adults with overweight and obesity
Evaluation of the effect of liraglutide therapy on body weight and insulin resistance.
Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study
The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis
High Glucose Impairs Cognitive Function through Inducing Mitochondrial Calcium Overload in Treg Cells
(GLP1 reduces the negative cognitive effects)
GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation
GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity
Harm
A Case Report of Systemic Allergic Reaction to the Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide
Impact of GLP-1 Agonists on Male Reproductive Health—A Narrative Review
The EMA and Glucagon-Like Peptide-1 Agonists: A Wake-Up Call
Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity
The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)
Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A scandinavian cohort study
No Increased Risk for Thyroid Cancer in Diabetic Patients Prescribed GLP-1 Medications Compared to Those Prescribed Insulin
Rhabdomyolysis Associated With Semaglutide Therapy: A Case Report
Appendicitis: A Hidden Danger of GLP-1 Receptor Agonists?
With other existing conditions
Management of type 2 diabetes in patients with compensated liver cirrhosis: Short of evidence, plenty of potential
Glucagon‐like peptide‐1 analogues in monogenic syndromic obesity: Real‐world data from a large cohort of Alström syndrome patients
Use of glucagon‐like peptide‐1 receptor agonists in eating disorder populations
Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis-associated cirrhosis
Action Mechanisms of Metformin Combined with Exenatide and Metformin Only in the Treatment of PCOS in Obese Patients
The long road to neuroprotection for Parkinson's disease
Benefits of administering GLP-1 analogs to patients with polycystic ovary syndrome, considering their effect on adipose tissue metabolism
Unveiling the Interplay of Klotho Protein, Chemotherapy-Induced Klotho Protein Deficiency, and the Pivotal Role of GLP-1 Agonists like Ozempic in Cancer Survivorship Patient Survival Rate after Chemotherapy Treatment
The Impact of Glucagon-like peptide-1 (GLP-1) Agonists on Hip and Knee Arthroplasty and Perioperative Considerations
An Atypical Presentation of Dulaglutide-Induced Pancreatitis Complicated by Superior Mesenteric Vein Thrombosis
Summary
Novel Therapies in Diabetes: A Comprehensive Narrative Review of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Beyond
Comparison of GLP-1 Receptor Agonists and Other Glucose-Lowering Agents on Cardiovascular Outcomes in Individuals with Type 2 Diabetes and Obesity
Glucagon‐like peptide agonists: A prospective review
Practice Patterns and Perspectives of the Off-Label Use of GLP-1 Agonists for Cosmetic Weight Loss
At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide
New methods/approaches/substances
OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes
📬 Get the latest GLP1 news straight to your inbox
